Across TCGA pan-cancer cohorts, ZNF100 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF100 data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF100 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF100 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LUAD, UCEC, and ESCA are the cancer types where ZNF100 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.220	0.714	<.001	42	view →
UCEC	DFS	Median	All	0.955	0.826	.013	22	view →
ESCA	OS	Median	All	0.234	0.703	.001	12	view →
STAD	OS	Median	III,IV	1.000	0.365	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF100 tumor-vs-normal RNA expression · all ZNF100 data types